Skip to main content
. 2020 Jul 22;64(8):e00757-20. doi: 10.1128/AAC.00757-20

TABLE 1.

MIC distributions for meropenem alone and combined with QPX7728 at various concentrations against 598 carbapenem-resistant strains of Enterobacteralesa

Treatment % of strains inhibited at MIC (μg/ml) of:
MIC50 (μg/ml) MIC90 (μg/ml)
≤0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 >64
MER alone 0.5 0.5 0.5 1.2 2.7 5.5 13.2 26.3 43.5 56.5 70.7 100 32 >64
MER with QPX at concn of:
    1 μg/ml 30.9 37.8 45.7 53.3 61.5 68.6 73.2 77.8 82.3 86.8 91.0 99.8 05 64
    2 μg/ml 39.3 52.7 64.0 72.4 77.4 81.6 84.6 87.5 90.1 93.5 96.3 100 0.125 16
    4 μg/ml 51.5 66.7 76.8 83.3 86.3 89.8 93.6 96.5 97.8 98.5 99.5 100 ≤0.06 4
    8 μg/ml 66.4 76.4 86.6 92.0 95.7 98.0 99.0 99.3 99.7 100 100 100 ≤0.06 0.5
    16 μg/ml 84.3 91.1 95.0 97.8 99.5 100 100 100 100 100 100 100 ≤0.06 0.125
a

The panel consisted of 324 strains producing serine carbapenemases from class A (n = 285; 274 KPC, 8 SME, and 3 NMC-A) and class D (n = 39), 224 strains producing metallo-beta-lactamases (151 NDM, 53 VIM, and 20 IMP), and 50 strains that did not carry any known carbapenemases but had a meropenem (MER) MIC of ≥4 μg/ml (non-carbapenemase-producing CRE). QPX, QPX7728.